In vivo development of amoxicillin and ceftriaxone resistance in Salmonella enterica serovar Typhi

Clin Microbiol Infect. 2019 Aug;25(8):1045-1047. doi: 10.1016/j.cmi.2019.03.015. Epub 2019 Mar 23.

Authors

G S E Tan¹, S Octavia², J W P Teo³, M L T Ang⁴, M-V La⁴, R T P Lin⁵, S Choudhury⁶, B S P Ang¹

Affiliations

¹ Communicable Diseases Centre, Institute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital Department of Infectious Diseases, Singapore.
² National Public Health Laboratory, Ministry of Health, Singapore. Electronic address: sophie.octavia@gmail.com.
³ Department of Laboratory Medicine, National University Hospital, Singapore.
⁴ National Public Health Laboratory, Ministry of Health, Singapore.
⁵ National Public Health Laboratory, Ministry of Health, Singapore; Department of Laboratory Medicine, National University Hospital, Singapore; Department of Microbiology and Immunology, National University of Singapore, Singapore.
⁶ Department of Laboratory Medicine, Tan Tock Seng Hospital, Singapore.

PMID: 30914348
DOI: 10.1016/j.cmi.2019.03.015

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Amoxicillin / adverse effects
Amoxicillin / pharmacology*
Amoxicillin / therapeutic use*
Anti-Bacterial Agents / adverse effects
Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use
Bacteria / drug effects
Bacteria / genetics
Bacteria / isolation & purification
Ceftriaxone / adverse effects
Ceftriaxone / pharmacology*
Ceftriaxone / therapeutic use*
Drug Resistance, Multiple, Bacterial* / drug effects
Drug Resistance, Multiple, Bacterial* / genetics
Feces / microbiology
Genome, Bacterial / genetics
Humans
Medication Adherence
Plasmids / genetics
Recurrence
Salmonella typhi / drug effects*
Salmonella typhi / genetics
Salmonella typhi / isolation & purification
Typhoid Fever / drug therapy*
Typhoid Fever / microbiology

Substances

Anti-Bacterial Agents
Ceftriaxone
Amoxicillin